AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03673267 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutricity
Description: Participants will use their smartphone or web-accessing device to access the Nutricity website to potentially increase nutrition literacy and set nutrition goals. Participants will have their own user name and password to access the site. Access to Nutricity will last approximately 3 months.
Study NCT03586609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given SC
Study NCT03586609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study NCT06398522 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Food for special medical purposes with calcium butyrate, zinc gluconate and vitamin D3
Description: Food for special medical purposes with functional release containing calcium butyrate, zinc gluconate and vitamin D3
Study NCT06398522 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01117623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 20 mg
Description: Participants in the dose-escalation cohort received a single 20 mg oral CP tablet of regorafenib on Day 1 of Cycle 1 followed by 1 day off treatment. On Day 3, once-daily continuous dosing with 20 mg oral co-precipitate (CP) tablets was initiated. A cycle was defined as 21 days. For Cycle 2 and subsequent cycles, regorafenib was administered once daily continuously on a 21-day cycle.
Study NCT01117623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 40 mg
Description: Participants in the dose-escalation cohort received a single 40 mg oral CP tablet of regorafenib on Day 1 of Cycle 1 followed by 1 day off treatment. On Day 3, once-daily continuous dosing with 40 mg oral CP tablets was initiated. A cycle was defined as 21 days. For Cycle 2 and subsequent cycles, regorafenib was administered once daily continuously on a 21-day cycle.
Study NCT01117623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 100 mg
Description: Participants in the dose-escalation cohort received a single 100 mg oral CP tablet of regorafenib on Day 1 of Cycle 1 followed by 1 day off treatment. On Day 3, once-daily continuous dosing with 100 mg oral CP tablets was initiated. A cycle was defined as 21 days. For Cycle 2 and subsequent cycles, regorafenib was administered once daily continuously on a 21-day cycle.
Study NCT01117623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 120 mg
Description: Participants in the dose-escalation cohort received a single 120 mg oral CP tablet of regorafenib on Day 1 of Cycle 1 followed by 1 day off treatment. On Day 3, once-daily continuous dosing with 120 mg oral CP tablets was initiated. A cycle was defined as 21 days. For Cycle 2 and subsequent cycles, regorafenib was administered once daily continuously on a 21-day cycle.
Study NCT01117623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 140 mg
Description: Participants in the dose-escalation cohort received a single 140 mg oral CP tablet of regorafenib on Day 1 of Cycle 1 followed by 1 day off treatment. On Day 3, once-daily continuous dosing with 140 mg oral CP tablets was initiated. A cycle was defined as 21 days. For Cycle 2 and subsequent cycles, regorafenib was administered once daily continuously on a 21-day cycle.
Study NCT01117623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCC Child-Pugh A expansion cohort: Regorafenib 100 mg
Description: Hepatocellular carcinoma (HCC) Participants with Child Pugh A in the expansion cohort received a single 100 mg oral CP tablet of regorafenib on Day 1 of Cycle 1 followed by 1 day off treatment. On Day 3, once-daily continuous dosing with 100 mg oral CP tablets of regorafenib was initiated. A cycle was defined as 21 days. For Cycle 2 and subsequent cycles, regorafenib was administered once daily continuously on a 21-day cycle.
Study NCT01117623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCC Child-Pugh B expansion cohort: Regorafenib 100 mg
Description: Hepatocellular carcinoma (HCC) Participants with Child Pugh B in the expansion cohort received a single 100 mg oral CP tablet of regorafenib on Day 1 of Cycle 1 followed by 1 day off treatment. On Day 3, once-daily continuous dosing with 100 mg oral CP tablets of regorafenib was initiated. A cycle was defined as 21 days. For Cycle 2 and subsequent cycles, regorafenib was administered once daily continuously on a 21-day cycle.
Study NCT01117623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NSCLC expansion cohort: Regorafenib 100 mg
Description: Non-small cell lung cancer (NSCLC) participants in the expansion cohort received a single 100 mg oral CP tablet of regorafenib on Day 1 of Cycle 1 followed by 1 day off treatment. On Day 3, once-daily continuous dosing with 100 mg oral CP tablets of regorafenib was initiated. A cycle was defined as 21 days. For Cycle 2 and subsequent cycles, regorafenib was administered once daily continuously on a 21-day cycle.
Study NCT00768963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab
Description: 0.5 mg subconjunctival ranibizumab 3 days prior to surgery
Study NCT00768963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab
Description: 0.5 mg subconjunctival ranibizumab at the time of surgery
Study NCT04598919 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saracatinab
Description: 125 mg once daily by mouth for 24 weeks
Study NCT04598919 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: once daily by mouth for 24 weeks
Study NCT02668315 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Transplantation of cord blood expanded with UM171
Description: Myeloablative or submyeloablative conditioning regimen followed by an expanded cord blood transplant
Study NCT02924675 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Three doses daily with lactose
Study NCT02946229 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Ultrasound scan
Description: Collection of ultrasound data sets that include routine ultrasound data (eg, extravascular lung fluid, cardiac velocity time integral and inferior vena cava) on the commercial GE Vivid S70 Ultrasound System which are used to test feasibility of next generation ultrasound algorithms being developed to process these data types.
Study NCT05610761 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Core stabilization exercises with Kegel exercises
Description: Core stabilization exercise program consists of two phases: teaching the basic movement (contraction of the Transversus abdominis and other muscles with diaphragmatic breathing) and incremental exercises added to the basic movement. The basic movement will be studied before each exercise and then the specified exercises will be added. The physiatrist will teach the exercise program to the patients. The first 6 of the 12 exercises classified according to the degree of difficulty will be performed for 5 weeks, and the next 5 weeks will be moved to the other 6 exercises. The exercises will be performed at least 3 days a week, with 10 repetitions of each movement, and the program will last for 10 weeks. Compliance with the exercise program will be questioned over the phone, and patients will be evaluated with a follow-up form before the study, at the 10th week, and at the 20th week. In addition, the Kegel exercise program specified in the other group will be applied.
Study NCT05610761 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Kegel exercises
Description: Kegel Exercises The exercise will start as 2 sets of 10 repetitions in the morning and evening, and after getting used to it, it will be increased to 3 sets of 10 repetitions per day.~The patient, lying on his back with his knees bent, feet slightly apart from each other, will try to lift the breech, urinary tract opening and vagina on the pelvic floor by counting to 5, and should not tighten your abdominal and leg muscles, and should not hold your breath while doing this exercise.~In this way, he will count up to 5 while contracting, then he will relax by counting to 10 (after getting used to it, the holding time will be increased to 10 seconds).
Study NCT02430610 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Irreversible electroporation (IRE)
Description: Irreversible Electroportion For Unresectable Uterine Cervical Neoplasms guide with ultrasound or/and CT.
Study NCT02430610 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NanoKnife
Study NCT02470871 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Eptacog alfa (activated) or pdFVII
Description: Comparator Drug 1: Recombinant activated FVII (rFVIIa). Subjects with eptacog alfa (activated) as their routine FVII replacement therapy will receive a single dose of eptacog alfa (activated) in the study.~Comparator Drug 2: Plasma-derived FVII (pdFVII). Subjects with pdFVII as their routine FVII replacement therapy will receive a single injection of pdFVII in the study.
Study NCT02470871 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CSL689
Description: Experimental Drug: Recombinant fusion protein, linking activated FVII with albumin (rVIIa-FP). Subjects will receive a single dose of CSL689 at either a low dose (Arm 1) or a high dose (Arm 2)
Study NCT00965991 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: patients received glyburide initial dose of 500 mg PO BID. Increased as necessary to a maximum dose of 2000 mg QD to control blood glucose
Study NCT00965991 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glyburide
Description: Initial dose of 2.5mg PO BID increased as necessary to a maximum dose of 20 mg (10mg BID) QD to control blood glucose
Study NCT01838889 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Culturally adapted psychological intervention (Positive Health Programme)
Description: This study will evaluate the efficacy of a group psychological intervention (PHP) based on the principles of Cognitive Behaviour Therapy in treating depression in postpartum women.
Study NCT04448080 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Micropulse Transscleral Laser Therapy for Glaucoma (MP-TLT)
Description: Intraocular pressure will be lowered by Micropulse Transscleral Laser Therapy for Glaucoma (MP-TLT) in patients with a diagnosis of glaucoma
Study NCT04448080 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Micropulse Transscleral Laser Therapy for Glaucoma (MP-TLT)
Description: Intraocular pressure will be lowered by Micropulse Transscleral Laser Therapy for Glaucoma (MP-TLT) in patients with a diagnosis of glaucoma
Study NCT02732145 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Three Rings Vulvoscopy (TRIV)
Description: Mapping of the vulvar lesions according to the three vulvar rings and specificity of the lesions during Three Rings Vulvoscopy technique (TRIV Form Data). Assessing of the data by the Vulvoscopy Index and the N-S-P Scheme.
Study NCT02732145 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Three Rings Vulvoscopy (TRIV)
Description: Mapping of the vulvar lesions according to the three vulvar rings and specificity of the lesions during Three Rings Vulvoscopy technique (TRIV Form Data). Assessing of the data by the Vulvoscopy Index and the N-S-P Scheme.
Study NCT02732145 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Histopathology
Description: Biopsy of the vulva in symptomatic patients, vulvar samples after labiaplasty in asymptomatic patients.
Study NCT02732145 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Histopathology
Description: Biopsy of the vulva in symptomatic patients, vulvar samples after labiaplasty in asymptomatic patients.
Study NCT00851136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Intravenous repeating dose
Study NCT00851136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX
Description: Intravenous repeating dose
Study NCT00851136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRO95780
Description: Intravenous repeating dose
Study NCT03482674 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DIMINI lifestyle intervention
Description: DIMINI lifestyle intervention consists of the DIMINI-kit which contains health information, a list of food recommendations with additional information on calories, serving size and weight (traffic light rating system), a nutrition and an exercise diary. Participants in the intervention group can choose between a paper-based version or an app-based version of the DIMINI-kit. In addition, the kit includes an elastic exercise band with exercise poster, a measuring tape for self-control of the waist size and a pedometer.
Study NCT04565314 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Plumpy'Mum
Description: Mothers will consume Plumpy'Mum (one packet daily) from enrollment (child age 0-3 months) for 3 months.
Study NCT01702428 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Priorix
Description: Subjects receive 1 dose of MMR vaccine which is administered subcutaneously in the triceps region of the left arm.
Study NCT01702428 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: M-M-R II
Description: Subjects receive 1 dose of MMR vaccine which is administered subcutaneously in the triceps region of the left arm.
Study NCT01702428 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Varivax
Description: Subjects receive 1 dose of VV vaccine which is administered subcutaneously in the triceps region of the right arm.
Study NCT01702428 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Varivax
Description: Subjects receive 1 dose of VV vaccine which is administered subcutaneously in the triceps region of the right arm.
Study NCT02564822 — intervention group
Intervention type: PROCEDURE
Intervention: Visual Stimulation
Description: volunteers will be invited to sit in a comfortable chair, in a calm and dark room, at 90 cm of distance from computer screen. It will be asked to fix his right eye visual field on a red point at the center of the screen (the left one will be blindfolded). Visual stimuli will be a black and White grid pattern, alternating at a frequency of 3.1 Hz.
Study NCT04599816 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levosimendan at a dose of 3 mcg/kg
Description: levosimendan will be administered intravenously at a dose of 3 mcg/kg after anesthesia induction
Study NCT04599816 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levosimendan at a dose of 6 mcg/kg
Description: levosimendan will be administered intravenously at a dose of 6 mcg/kg after anesthesia induction
Study NCT04599816 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levosimendan at a dose of 12 mcg/kg
Description: levosimendan will be administered intravenously at a dose of 12 mcg/kg after anesthesia induction
Study NCT01702428 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Havrix
Description: Subjects receive 1 dose of HAV vaccine which is administered intramuscularly in the anterolateral region of the right thigh.
Study NCT01188018 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Advice (BA)
Description: Participants in this arm will receive a single session of brief advice. A counselor will briefly discuss the risks associated with smoking.
Study NCT01188018 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Description: Subjects will receive 4 counseling sessions (over 18 weeks) in which their thoughts about their smoking will be discussed. Two of these counseling sessions will be performed in person (weeks 0 and 12) and the remaining two will be over the phone(weeks 6 and 18).
Study NCT01188018 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education (HE)
Description: Subjects will receive 4 counseling sessions (over 18 weeks)in which they will receive educational information about the risks of smoking and the benefits of quitting. Two of these counseling sessions will be performed in person (weeks 0 and 12) and the remaining two will be over the phone (weeks 6 and 18).
Study NCT01300286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RiaSTAP
Description: One time dose of 70 mg/kg will be administered intravenously.
Study NCT03690414 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Experimental BHVI2
Description: Experimental BHVI2 eye drops
Study NCT03690414 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atropine sulfate 0.02% eye drops
Description: Atropine eye drops
Study NCT03690414 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Combination eye drops
Description: Combination eye drops with experimental BHVI2 plus 0.02% atropine
Study NCT03453749 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Salovum
Description: Salovum is freeze dried egg yolk, highly enriched with anti-secretory factor. Salovum is registered as a medical food by the EU
Study NCT06316661 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: stress perfusion cardiac magnetic resonance
Description: stress perfusion cardiac magnetic resonance according to guidelines, with quantitative evaluation for microvascular dysfunction assessment
Study NCT06316661 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: cardiopulmonary exercise test
Description: bike exercise with ECG and non invasive respiratory gas exchange monitoring
Study NCT00447954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NT-501 implant
Description: High Dose
Study NCT00447954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NT-501 implant
Description: Low Dose
Study NCT00447954 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Procedure
Description: Sham Procedure
Study NCT00795626 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Systematic education in the reduction of the risk estimate to cardiovascular events
Description: Systematic education during 4 assessment throughout one year
Study NCT02599467 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ULNT 1 and EMG recording
Description: While the ULNT 1 was performing, EMG muscle activity form biceps brachii and triceps brachii were recorded. The maneuver was stopped to measure abduction, external rotation and elbow flexion range of motion (ROM) with a goniometer. Three measurements were performed: measure 1) when the first sense of tightness perceived by the subject appeared; measure 2) when evoked muscle activity increased on EMG record; measure 3) when sense of final resistance perceived by the investigator appeared. Considering the increase of symptoms with contralateral or decrease of symptoms with ipsilateral cervical side bending as mandatory positivity criterion.
Study NCT02599467 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ULNT 1 and EMG recording
Description: While the ULNT 1 was performing, EMG muscle activity form biceps brachii and triceps brachii were recorded. The maneuver was stopped to measure abduction, external rotation and elbow flexion range of motion (ROM) with a goniometer. Three measurements were performed: measure 1) when the first sense of tightness perceived by the subject appeared; measure 2) when evoked muscle activity increased on EMG record; measure 3) when sense of final resistance perceived by the investigator appeared. Considering the increase of symptoms with contralateral or decrease of symptoms with ipsilateral cervical side bending as mandatory positivity criterion.
Study NCT02589093 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stimulation
Study NCT00521586 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: 13 valent pneumococcal conjugate vaccine
Description: TIV +13vPnC at dose 1 placebo at dose 2, one month after dose 1 13vPnC at year 5
Study NCT01702428 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Havrix
Description: Subjects receive 1 dose of HAV vaccine which is administered intramuscularly in the anterolateral region of the right thigh.
Study NCT00521586 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: 13 valent pneumococcal conjugate vaccine
Description: TIV + placebo at dose 1 13vPnC at dose 2, one month after dose 1 and 13vPnC at year 5
Study NCT01702428 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevnar 13
Description: US subjects receive 1 dose of PCV-13 vaccine which is administered intramuscularly in the anterolateral region of the left thigh.
Study NCT01702428 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevnar 13
Description: US subjects receive 1 dose of PCV-13 vaccine which is administered intramuscularly in the anterolateral region of the left thigh.
Study NCT02701582 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenylephrine
Description: if Mean arterial pressure (MAP) is \< = 65, Stroke volume variation (SVV) \< 13 and Cardiac Index is >=2.2 Phenylephrine is administered
Study NCT02701582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Description: if Mean arterial pressure (MAP) is \< = 65, Stroke volume variation (SVV) \< 13 and Cardiac Index is >=2.2 Phenylephrine is administered
Study NCT02701582 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrine
Description: if Mean arterial pressure (MAP) is \< = 65, Stroke volume variation (SVV) \< 13 and Cardiac Index is \< 2.2 Epinephrine is administered
Study NCT02701582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine
Description: if Mean arterial pressure (MAP) is \< = 65, Stroke volume variation (SVV) \< 13 and Cardiac Index is \< 2.2 Epinephrine is administered